International Journal of
INTELLIGENT SYSTEMS AND APPLICATIONS IN ENGINEERING
ISSN:2147-6799 www.ijisae.org Original Research Paper

Prediction of the Side Effects Associated with the Drug-Drug Interaction in Human Beings using Chaotic Particle Swarm Optimisation Based Deep Radial Networks

[1]Mr. M. Arunkumar, [2]Dr. T.S. Baskaran

Submitted: 06/02/2024 **Revised**: 14/03/2024 **Accepted**: 20/03/2024

Abstract: Prediction of the side effects associated with the drug-drug interaction (DDI) in human beings using Chaotic Particle swarm optimisation (CPSO) based deep radial networks (DRN). As drug classes, feature vectors, pathways, target, and enzymes are utilised; afterwards, CPSO is utilised to extract feature interactions between these drug-related entities. We made use of DRN as a predictor of events associated with DDIs by basing it on the representation of characteristics. The findings indicate that when compared to several other metrics that are state-of-the-art, DRN-DDI performs better. In the meanwhile, we discuss the ways in which individual and combinational characteristics contribute. DRN-DDI provides greater advantages than other methods when it comes to the prediction of DDI events.

Keywords: Prediction, side effects, drug-drug interaction, Chaotic Particle swarm optimisation, deep radial networks

1. Introduction

When two or more medications are taken at the same time, the risk of experiencing negative interactions between the drugs increases (DDI). Interactions between medications can boost or lower the effectiveness of each one, lead to the development of adverse effects that could endanger a patient life, and even result in the removal of a pharmaceutical from the market [1].

To make matters even more complicated, twenty percent of the older population simultaneously takes ten or more drugs. Patients have a greater possibility of developing an adverse response to one of the numerous medications currently available on the market as more of these products are introduced. As a result, DDI prediction in clinical practise is becoming increasingly important but also increasingly challenging [2].

Although in vivo and in vitro tests have the potential to be helpful in DDI detection, it is not always possible to use them due to a lack of resources or because of the high costs involved. The development of computational approaches for addressing issues with DDI identification is of the utmost importance. In the modern era, researchers have access to two distinct computational methods for the purpose of DDI detection: 1) extrapolating from known DDI to predict new DDI, and 2) extracting DDI from literature, electronic medical records, and anecdotal reports [3].

Most of these recent studies [4-5] have concentrated on approaches that are based on chemical structures; however, they have also taken into consideration aspects like adverse effects, the pharmacology of medications, and protein sequences. It has been hypothesised that, in the same way that two proteins that share a similar sequence are more likely to be targeted by the same medications [6], two molecules that share a similar chemical structure are also more likely to target common proteins, and this similarity in chemical structure can be related to the efficacy of the drug.

There have been a variety of research [7-9] that have made the attempt to combine the chemical structures of medicinal agents with the sequences of proteins. Enzyme Commission (EC) have both been used as measurements of the similarity of one protein to another. On the other hand, the Tanimoto score, and a signature kernel have both been used to quantify the similarity of one medication to another. In addition, the use of approaches that make use of similarities between the drug and the protein has resulted in an improvement in the accuracy of the prediction of DDI.

Conducting studies on the negative side effects of various medications is a productive method. It possible that different medications that produce similar adverse effects are targeting the same proteins. On the other

[1]*Research Scholar, PG & Research Department of Computer Science, A. Veeriya Vandayar Memorial Sri Pushpam College (Autonomous), Poondi - 613503, Thanjavur, "Affiliated to Bharathidasan University, Tiruchirappalli-620024", TamilNadu, India.*
E-Mail: arunk145@gmail.com
[2]*Associate Professor& Research Supervisor, PG & Research Department of Computer Science, A Veeriya Vandayar Memorial Sri Pushpam College (Autonomous), Poondi - 613503, Thanjavur, "Affiliated to Bharathidasan University, Tiruchirapalli-620024", TamilNadu, India.*
E-Mail: t_s_baskaran@yahoo.com

hand, you may only use this strategy when dealing with medications whose potential adverse effects have already been uncovered. It is also beneficial to understand the pharmacological effects of the drug, as well as its side effects, precautions, uses, qualities, and so on. The researchers investigated the ways in which the pharmacological space and the chemical space crossed with one another. According to the findings of the study, it is possible to accurately forecast drug-target interactions by analysing pharmacological space.

In this article, we study how the DDI can be used to anticipate how a medicine will interact with its target. The precision of the DDI predictions that are generated by deep learning is contingent on a few different characteristics. When we consider the fact that two pharmaceuticals that have a high degree of similarity, as determined by DDI, are likely to target the same proteins, we can conclude that the degree of similarity that exists between the two medications ought to affect the accuracy of the prediction. The accuracy of the prediction is reliant on gold-standard interactions, and there are a multitude of drug-related databases from which to pick and evaluate DDI.

2. Related works

Research aimed at predicting DDI has resulted in the publication of several methodologies, including one known as physiologically based data mining from clinical data. The ADME properties of a drug can be represented by a PBPK model in a human body by using a set of equations. This model is used to study how drugs work in humans [9].

The ability to predict DDIs has been demonstrated by structural similarities. This is the logic that underpins this proposition. Based on the structural similarities between different medications and molecular fingerprints, Vilar et al. [10] predicted DDIs using matrix transformation method. The researchers developed prediction algorithms that took use of combined similarity metrics, including those for interaction profiles, unfavourable effects, and targets.

To achieve this goal, the inferring drug interactions algorithm is developed. This algorithm predicts DDI involving CYP and PD. There was also a focus on the utility of using 3D structural data for DDI prediction [11] because this data type can pick up details that are lost when using only 2D information. The utilisation of similarity was crucial in the accomplishment of this objective.

Luo et al. [12] to establish a DDI prediction using protein interaction profiles. This was done by analysing the chemical-protein interaction profiles. To accurately forecast DDIs on DDI networks, machine learning approaches were utilised. These techniques combined behavioural, pharmacological, structural, and genetic similarities.

Using two distinct chemical descriptors, QSAR models for DDI prediction were developed [13], with a combined accuracy ranging from 72% to 79%. In addition, research is carried out for DDI forecasting based on the knowledge that is already available. The DDI prediction made by Huang et al. [14] utilising a DDI network according to the study that they conducted. Zazo et al. [15] were able to infer DDI by utilising semantic web rule language (SWRL) in conjunction with DDI metadata, which included DDI kinds, procedures, and applications.

DDI predictions were produced by Cami et al. [16] by making use of DDI infrastructure that already existed. A Pharmacointeraction network (PIN) model for the prediction of DDI was just recently established by merging clinical side with the event reporting system maintained by the FDA. The utilisation of EHRs also made it possible to identify and rank the severity of DDI adverse events.

3. Proposed Method

We present a novel method for predicting DDI events; we refer to it as CNN-DDI. A combinational feature selection module and a prediction module based on a Deep Radial Network (DRL) make up the bulk of the approach. Both modules are based on neural networks. The inputs needed for the CNN model can be obtained by combining the four pharmacological features presented in Figure 1. The resultant list of features only has a limited number of dimensions. After that, we determine the probability of different DDI kinds by employing a deep DRL model.



Figure 1: Proposed Framework

3.1. CPSO based Feature Extraction

Particle swarm optimization (PSO) is an evolutionary method that makes use of swarm intelligence. This programme determines the best course of action by simulating the behaviour of a flock of birds flying at different velocities and heights. The speeds of all these birds are adjusted so that they are consistent with their individual histories as well as the places of their neighbours within the exploratory search space.

Each of the birds that make up the solution group constitutes a particle. The PSO method conducts a series of iterative searches to locate the best answer. Let imagine that there are D dimensions deep within a swarm that contains N particles. The velocity of the k^{th} particle is defined by the equation $V_k = [V_k^1, V_k^2,...,V_k^D]$, while its position $X_k = [X_k^1, X_k^2,...,X_k^D]$ is defined by the equation.

The velocity of the k^{th} particle receives a fresh update at the beginning of each cycle.

$$V_{kd}^{i+1} = \omega * V_{kd}^{i} + C_1 * rand_1 * \left(pbest_{kd}^{i} - X_{kd}^{i} \right) + C_2 * rand_2 * \left(gbest_{d}^{i} - X_{kd}^{i} \right)$$

The range of the vector $k \in \{1,2,3...,N\}$, the range of the vector d $\in$ {1,2,3..., D}, the range of the vector $i \in \{1,2,3...i\}$, and the X_{kd}^{i} values for the position $pbest_{kd}^{i}$ and $gbest_{d}^{i}$ of the k^{th} particle in the d^{th} dimension for the i^{th} iteration and the velocity V_{kd}^{i} of the k^{th} particle in the d^{th} dimension for the i^{th} iteration are as follows:

The acceleration coefficients C_1 and C_2 are constants, and the inertia weight is also a constant. Random integers $rand_1$ and $rand_2$ are selected at random from a uniform distribution between 0 and 1, and the inertia weight ω is also a constant. After initialising it to a quantity that is more than one but less than one in the first iteration, we then lower it in following iterations by the same linear amount. The value ω determines how much weight should be given to the previous direction of travel. It is demonstrated how a Markov chain property can be utilised to update the position of the k^{th} particle in the $N \times D$ dimension of the search space.

$$X_{kd}^{i+1} = X_{kd}^{i} + V_{kd}^{i+1}$$

CSO

An example of a bio-inspired meta-heuristic algorithm is Cuckoo Search (CS). When it comes to solving the problem of global optimization, the CS algorithm is superior to PSO, GA, DE, and other meta-heuristic algorithms in terms of robustness and generalizability since it has fewer control parameters and a more even distribution of exploration and exploitation.

A algorithm that was conceived after being influenced by the peculiar actions of cuckoo birds. to find the most effective answer to a search challenge, an approach that combined cuckoo breeding with the Lévy flight behaviour was utilised. The CS algorithm, like other meta-heuristic algorithms, begins with a random initial population. However, in the same way as the HS algorithm studies some form of selection and/or elitism, the CS algorithm also begins with a random initial population.

In the CS algorithm, each pattern is interpreted as a cuckoo nest, and each pattern component is interpreted as an individual cuckoo egg. The CS algorithm can be written as.

$$X_{t+1;i} = X_{t;i} + \alpha \otimes Lévy(\lambda)$$

where

$X_{t;i}$ - current solution,

$X_{t+1;i}$ - next generated solution with Lévy flight,

t - current generation,

$\otimes$ - entry-wise multiplication, and α>0 is a scaling factor of the step size that depends on scales of the given problem of interest.

It is possible to express the size of a problem using either the $\alpha=O(L/10)$ or $\alpha=O(L/100)$, with the former being more appropriate for more manageable issues. Big O notation is used to describe how difficult the algorithm is to execute in terms of time. Each of the challenges requires a different group of characteristics to be exercised in relation to the scale L.

Lévy(λ) is a random movement that is based on Lévy flight. This random movement is more efficient than a random walk-in other algorithm such as the DE, ABC, PSO, and so on. The search area is going to be expanded or diversified; thus, we are going to take over the search space.

Lévy() function is derived from a Lévy distribution that possesses both an infinite variance and an infinite mean.

$$\text{Lévy} \sim u = t^{-\lambda};\ 1<\lambda\leq 3$$

Random numbers '~' drawn from a Lévy distribution with a heavy-tailed power-law distribution for the step size are indicated, where λ is the power coefficient. These numbers were picked at random and come from the Lévy distribution. The function $P(x)$ can be found as a probability density of a random variable x.

Lévy flights can be used to speed up the process of local exploration. Lévy flights can cover a huge part of the search space for the variables. If the CS algorithm is to avoid being trapped in a local optimum, a significant number of the new solutions need to be generated by far-field randomization. This ensures that the position of each new solution is adequately remote from the best solution that has been achieved thus far.

The cuckoo search can conduct both broad investigations and targeted exploitation, given that the steps produced by the Lévy walk contains both minute and substantial components. Even though there are alternative methods for producing Lévy distributions, stands out as one of the most efficient and yet straightforward methods. Using this method, symmetric Lévy stable distributions are produced for the random integers that are produced. The Lévy walk is a simple method for generating new solutions that can be used in a variety of contexts.

$$X_{t+1} = X_t + step\ size \otimes N(0,1)$$

The result of running the Mantegna algorithm is the Lévy random walk, which is denoted by

$$Step\ size = 0.01*(u/|v|^{\beta}) \otimes (X_t - X_{best})$$

This is an example of a cuckoo walk, in which the value 0.01 determines the size of each step. u and v are normally distributed stochastic variables generated from $u \sim N(0, \sigma^2)$ and $v \sim N(0, 1)$, and σ^2 is the variance, and X_{best} is the best global solution and X_t is the current solution. Step size $\otimes$ refers to the length of the walk step and that gets formed from $u \sim N(0, \sigma^2)$ and $v \sim N(0, 1)$. The gamma function Γ is an extension of the factorial function for positive numbers. Additionally, β= 1.5 represents the distribution-controlling variable with values ranging from $0 \leq \beta \leq 2$.

$$\sigma^2 = \left\{ \frac{\Gamma(1+\beta)\sin\left(\frac{\pi\beta}{2}\right)}{\Gamma\left(\frac{1+\beta}{2}\right)\beta * 2\left(\frac{\beta-1}{2}\right)} \right\}^{\frac{1}{\beta}}$$

The value of has been confirmed to be 1.5, according to the findings can be used to determine the variance:

$$X_{t+1} = X_t + r \otimes H(p_a - r) \otimes (X_j - X_k)$$

Calculating a local random walk that is intended to exploit or intensify the search space can be done. X_j and X_k are two solutions that were picked at random, $H(u)$ is a Heaviside function $H(u) = \begin{cases} 1 & if\ u > 0 \\ 0 & if\ u < 0 \end{cases}$ if $u< 0$, p_a is the probability that a host bird will come across a cuckoo egg, and random number r that was obtained from a uniform distribution in the range [0,1]. The literature describes a great number of problems with global optimization, and the CS approach can quickly determine the optimal solutions with only a limited number of tuning parameters.

CPSO

One type of algorithm that is a hybrid is one that integrates the most beneficial aspects of several different algorithms into a single algorithm. Most of the time, hybridization will result in improved levels of computation precision or speed. We expect that by combining two or more algorithms, we will be able to take use of the positive aspects of each while simultaneously minimising the negative aspects of the algorithms to the greatest extent possible.

Within the realm of optimization, the PSO method holds its own against other prominent approaches. However, due to the speed with which it converges, it can reach a solution to challenging problems quicker than other methods. When compared to other optimization strategies, the CS algorithm is frequently the method of choice when attempting to resolve complex issues. The exploratory capability of the CS algorithm has been improved, even though it converges at a little slower rate.

There is a compromise to be made between the degree of convergence and the degree of precision. The hybridization of cuckoos is being done with the intention of providing each cuckoo with information about their current location and assisting in the relocation to a place that is more favourable. PSO-based adjustments are made to the position and velocity of each individual cuckoo in this algorithm.



Figure 2: Flowchart of CPSO algorithm

3.2. Classification using DRN

As soon as the module notifies the countermeasure device that there is a problem, the countermeasure device will immediately begin its search for the DDI that is causing the issue. To monitoring the activity that takes place on the network, a DL technique that is based on an RBF model is utilised.

During the process of nonlinear mapping, a hidden layer network is utilised. This network combines supervised and unsupervised learning with linear perceptrons to achieve optimal results. The similarities that exist between the input vector and the prototype vector are used to generate a normal distribution for the output value, which has a range that goes from 0 to 1 and takes the shape of a normal distribution with a range that goes from 0 to 1.

4. Results and Discussions

The quality and quantity of the data that is now accessible are extremely important factors in the prediction of drug-target interactions. Although in recent years several new data sources pertaining to drugs and proteins have become accessible, the variety of data sources that are possible remains vast.

The number of drugs and proteins varies, as does the number of interactions between drugs and their targets; some interactions may not be included in each data set, while other data sets may contain false interactions. In addition, the identifiers for medications and proteins are different, making it difficult to aggregate data from many sources.

To determine how accurate our predictions were, we used a method called 5-fold cross validation. Drug and drug-target pairs are each randomly divided into five groups, and the matching kernel matrix is also divided into five groups. This is done so that each group can be analysed separately.

One of the groups will act as the subject of the experiment, while the other four will be used for teaching purposes. Following the random division of the test set into five groups, five separate calculations are made to determine the probability of interactions between drug-target combinations within each of the five groups.



Figure 3: Accuracy of Feature extraction



Figure 4: Accuracy of Classification



Figure 5: Precision of Classification



Figure 6: Recall of Classification



Figure 7: F-Measure of Classification

Every DDI is tested as in Figure 3 - 7 using this 5x5-fold cross validation procedure. The result of simulation shows that the proposed method achieves higher rate of accuracy, precision, recall and F-measure than the existing QSAR, SWRL and PIN models.

5. Conclusions

In the paper, we presented a novel algorithm for calculating the DDI estimates. As a first step, we begin the process of extracting feature interactions by using pharmacological classes, targets, pathways, and enzymes as feature vectors. To determine how effectively our strategy works, we evaluate it in comparison to the most recent and cutting-edge methods. The findings indicate that DDI performs remarkably well in comparison to other metrics that are state-of-the-art. In parallel to this, we discuss the ways in which individual traits and the combination of those features contribute. When it comes to predicting DDI occurrences, DDI offers a few benefits that are hard to beat. to make up for the increased amount of time that it presently requires, we are planning to make efforts in the future to improve the efficiency of DDI.

References

[1] Jang, H. Y., Song, J., Kim, J. H., Lee, H., Kim, I. W., Moon, B., & Oh, J. M. (2022). Machine learning-based quantitative prediction of drug exposure in drug-drug interactions using drug label information. *npj Digital Medicine*, *5*(1), 88.

[2] Hou, X., You, J., & Hu, P. (2019, February). Predicting drug-drug interactions using deep neural network. In *Proceedings of the 2019 11th International Conference on Machine Learning and Computing* (pp. 168-172).

[3] Zhang, Y., Qiu, Y., Cui, Y., Liu, S., & Zhang, W. (2020). Predicting drug-drug interactions using multi-modal deep auto-encoders based network embedding and positive-unlabeled learning. *Methods*, *179*, 37-46.

[4] Olayan, R. S., Ashoor, H., & Bajic, V. B. (2018). DDR: efficient computational method to predict drug-target interactions using graph mining and machine learning approaches. *Bioinformatics*, *34*(7), 1164-1173.

[5] Wang, Y., & Zeng, J. (2013). Predicting drug-target interactions using restricted Boltzmann machines. *Bioinformatics*, *29*(13), i126-i134.

[6] Chu, Y., Shan, X., Chen, T., Jiang, M., Wang, Y., Wang, Q., ... & Wei, D. Q. (2021). DTI-MLCD: predicting drug-target interactions using multi-label learning with community detection method. *Briefings in bioinformatics*, *22*(3), bbaa205.

[7] Shi, H., Liu, S., Chen, J., Li, X., Ma, Q., & Yu, B. (2019). Predicting drug-target interactions using Lasso with random forest based on evolutionary information and chemical structure. *Genomics*, *111*(6), 1839-1852.

[8] Fu, G., Ding, Y., Seal, A., Chen, B., Sun, Y., & Bolton, E. (2016). Predicting drug target interactions using meta-path-based semantic network analysis. *BMC bioinformatics*, *17*(1), 1-10.

[9] Tanvir, F., Islam, M. I. K., & Akbas, E. (2021, October). Predicting drug-drug interactions using meta-path based similarities. In *2021 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB)* (pp. 1-8). IEEE.

[10] Vilar, S., Harpaz, R., Uriarte, E., Santana, L., Rabadan, R., & Friedman, C. (2012). Drug—drug interaction through molecular structure similarity analysis. *Journal of the American Medical Informatics Association*, *19*(6), 1066-1074.

[11] Vilar, S., Uriarte, E., Santana, L., Friedman, C., & P Tatonetti, N. (2014). State of the art and development of a drug-drug interaction large scale predictor based on 3D pharmacophoric similarity. *Current Drug Metabolism*, *15*(5), 490-501.

[12] Luo, H., Zhang, P., Huang, H., Huang, J., Kao, E., Shi, L., ... & Yang, L. (2014). DDI-CPI, a server that predicts drug-drug interactions through implementing the chemical-protein interactome. *Nucleic acids research*, *42*(W1), W46-W52.

[13] Zakharov, A. V., Varlamova, E. V., Lagunin, A. A., Dmitriev, A. V., Muratov, E. N., Fourches, D., ... & Nicklaus, M. C. (2016). Qsar modeling and prediction of drug-drug interactions. *Molecular pharmaceutics*, *13*(2), 545-556.

[14] Huang, H., Zhang, P., Qu, X. A., Sanseau, P., & Yang, L. (2014). Systematic prediction of drug combinations based on clinical side-effects. *Scientific reports*, *4*(1), 7160.

[15] Herrero-Zazo, M., Segura-Bedmar, I., Hastings, J., & Martinez, P. (2015). DINTO: using OWL ontologies and SWRL rules to infer drug-drug interactions and their mechanisms. *Journal of chemical information and modeling*, *55*(8), 1698-1707.

[16] Cami, A., Manzi, S., Arnold, A., & Reis, B. Y. (2013). Pharmacointeraction network models predict unknown drug-drug interactions. *PloS one*, *8*(4), e61468.